Company intelligence / Profile preview

Tabby Therapeutics

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Tabby Therapeutics is developing a novel cell therapy platform based on engineered B cells for cancer immunotherapy. Their preclinical data demonstrate robust immune responses and successful engraftment in animal models. The company aims to address significant unmet needs in solid tumor treatment by leveraging the unique properties of B cells to orchestrate multi-modal anti-tumor immunity.

Therapeutic areas: Oncology
Modalities: Engineered B cells (cell therapy)Potentially gene editing (inferred from "site-specific" engineering)
Industry: Biotech

Drug pipeline

1 asset

Engineered B Cell therapy

Preclinical

Partnerships

Arkin Bio/Arkin Capital as co-founder/investor partner

Beyond the preview

Go deeper on Tabby Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tabby Therapeutics.

Explore the full profile